These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 1700945)
1. Pneumothorax following cytotoxic chemotherapy in malignant lymphoma. Hsu JR; Chang SC; Perng RP Chest; 1990 Dec; 98(6):1512-3. PubMed ID: 1700945 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of advanced Hodgkin lymphoma]. Kreissl S; Borchmann P Dtsch Med Wochenschr; 2013 Jun; 138(23):1212-4. PubMed ID: 23720173 [No Abstract] [Full Text] [Related]
3. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149 [TBL] [Abstract][Full Text] [Related]
4. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma. Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327 [TBL] [Abstract][Full Text] [Related]
5. Bleomycin-Induced Flagellate Dermatitis. Turan Erkek E; Karaali CN; Yılmaz G; Gültürk E Turk J Haematol; 2019 May; 36(2):138-140. PubMed ID: 30600679 [No Abstract] [Full Text] [Related]
6. [Treatment of metastatic breast cancer]. Yahalom J; Biran S; Sulkes A Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868 [No Abstract] [Full Text] [Related]
7. Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients. Bairey O; Gabbay U; Blickstein D; Stark P; Prokocimer M; Epstein O; Shaklai M; Lahav J Hematol Oncol; 1997 Aug; 15(3):121-7. PubMed ID: 9600111 [TBL] [Abstract][Full Text] [Related]
8. Predicting neutropenia after chemotherapy for lymphoma. Watkins SM Leuk Lymphoma; 1993 Jan; 9(1-2):107-9. PubMed ID: 7682881 [No Abstract] [Full Text] [Related]
9. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235 [TBL] [Abstract][Full Text] [Related]
10. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592 [TBL] [Abstract][Full Text] [Related]
11. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Busia A; Laffranchi A; Viviani S; Bonfante V; Villani F Anticancer Res; 2010 Oct; 30(10):4381-7. PubMed ID: 21036768 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of survival in Hodgkin's lymphoma. Canellos GP; Niedzwiecki D; Johnson JL N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568 [No Abstract] [Full Text] [Related]
14. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593 [TBL] [Abstract][Full Text] [Related]
15. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Brosteanu O; Hasenclever D; Loeffler M; Diehl V; Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867 [TBL] [Abstract][Full Text] [Related]
16. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709 [TBL] [Abstract][Full Text] [Related]
17. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype. Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583 [TBL] [Abstract][Full Text] [Related]
19. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas]. Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289 [TBL] [Abstract][Full Text] [Related]
20. MOPP, ABVD, or both to treat Hodgkin's disease. Aisenberg AC N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765 [No Abstract] [Full Text] [Related] [Next] [New Search]